Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: OTC US
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

ReGeneRx Biopharmaceuticals Inc

+ Add to Watchlist

RGRX:US

0.2500 USD 0.0086 3.56%

As of 17:20:00 ET on 03/05/2015.

Snapshot for ReGeneRx Biopharmaceuticals Inc (RGRX)

Open: 0.2300 Day's Range: 0.2300 - 0.2500 Volume: 33,655
Previous Close: 0.2414 52wk Range: 0.1005 - 0.2800 1-Yr Rtn: +25.00%

Stock Chart for RGRX

No chart data available.
  • RGRX:US 0.2500
  • 1D
  • 1M
  • 1Y
0.2414
Interactive RGRX Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for RGRX

Current P/E Ratio (ttm) -
Estimated P/E(-) -
Relative P/E vs. SPX -
Earnings Per Share (ttm) -0.0214
Est. EPS -
Est. PEG Ratio -
Market Cap (M USD) 25.33
Shares Outstanding (M) 101.32
30 Day Average Volume 137,708
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 04/06/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for RGRX

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for RGRX

RegeneRx Biopharmaceuticals, Inc. is focusing on the commercialization of Thymosin beta 4, a 43 amino acid peptide. The Company is concentrating its efforts on the use of Thymosin beta 4 for the treatment of injured tissue and non-healing wounds to enable more rapid repair and/or tissue regeneration.

Allan L GoldsteinChairman/Chief Scientific AdvisorJ J FinkelsteinPresident/CEO
Alan KleinInterim Chief Business Officer
More Company Profile & Key Executives for RGRX

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil